Table 1 Correlation of UPS22 expression with clinical characteristics of patients with gastric cancer
Characteristics | n | USP22-positive (%) | USP22-negative (%) | P-value |
|---|---|---|---|---|
Gender | Â | Â | Â | 0.249 |
 Male | 65 | 53 (81.5) | 12 (18.5) |  |
 Female | 23 | 16 (69.6) | 7 (30.4) |  |
Age | Â | Â | Â | 0.338 |
 < 60 | 29 | 21 (72.4) | 8 (27.6) |  |
 ≥ 60 | 59 | 48 (81.4) | 11 (18.6) |  |
Tumor diameter | Â | Â | Â | 1.000 |
 < 5 cm | 29 | 23 (79.5) | 6 (20.5) |  |
 ≥ 5 cm | 59 | 46 (78.0) | 13 (22.0) |  |
Lesion site | Â | Â | Â | 0.101 |
 Upper third | 18 | 17 (94.4) | 1 (5.6) |  |
 Middle third | 28 | 19 (67.9) | 9 (32.1) |  |
 Lower third | 42 | 33 (78.5) | 9 (21.5) |  |
T stage | Â | Â | Â | 0.019 |
 T1–2 | 12 | 6 (50) | 6 (50) |  |
 T3–4 | 76 | 63 (82.9) | 13 (17.1) |  |
N stage | Â | Â | Â | 1.000 |
 N0 | 20 | 16 (80.0) | 4 (20.0) |  |
 N1–3 | 68 | 53 (77.9) | 15 (22.1) |  |
M stage | Â | Â | Â | 1.000 |
 M0 | 85 | 66 (77.6) | 19 (22.4) |  |
 M1 | 3 | 3 (100) | 0 (0) |  |
Disease stage | Â | Â | Â | 0.995 |
 I–II | 37 | 29 (78.4) | 8 (21.6) |  |
 III–IV | 51 | 40 (78.4) | 11 (21.6) |  |
Histologic grade | Â | Â | Â | 1.000 |
 II | 26 | 21 (80.8) | 5 (19.2) |  |
 III | 62 | 48 (77.4) | 14 (22.6) |  |